glp 1 studies Researchers at UC Irvine issue a warning that GLP-1RAs may be dangerous for children GLP-1-based therapies for diabetes, obesity

Do GLP-1 medications cause muscle loss

Evidence-based comparison of retatrutide (GIP/GLP-1/glucagon triple agonist) and survodutide (GLP-1/glucagon dual agonist) for weight loss, MASH, and metabolic disease based on Phase 2 clinical trial data.

Starting in mid-2026, Medicare will begin covering these drugs for select patient groups and state Medicaid programs have the option to adopt similar coverage at these discounted rates

Have patients been harmed by unsafe drug compounding

This retrospective cohort study evaluated changes in time in therapeutic range (TTR) among patients receiving warfarin during the 6 months before and after GLP-1 RA initiation, using real-world data from the TriNetX Research Network

About three million Canadian adults are currently taking GLP-1 drugs such as Ozempic or Mounjaro and many more would like to